Mirabella Financial Services LLP Grows Stock Position in The Clorox Company (NYSE:CLX)

Mirabella Financial Services LLP lifted its stake in The Clorox Company (NYSE:CLXFree Report) by 1.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,790 shares of the company’s stock after buying an additional 164 shares during the period. Mirabella Financial Services LLP’s holdings in Clorox were worth $1,432,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Advisors Asset Management Inc. increased its holdings in shares of Clorox by 257.5% in the first quarter. Advisors Asset Management Inc. now owns 11,228 shares of the company’s stock worth $1,719,000 after buying an additional 8,087 shares during the period. Catalyst Capital Advisors LLC bought a new stake in shares of Clorox in the third quarter worth about $54,000. Raymond James & Associates grew its stake in shares of Clorox by 32.8% in the second quarter. Raymond James & Associates now owns 267,632 shares of the company’s stock worth $36,524,000 after purchasing an additional 66,149 shares during the last quarter. M&G Plc bought a new stake in shares of Clorox in the second quarter worth about $876,000. Finally, Cetera Investment Advisers grew its stake in shares of Clorox by 140.6% in the first quarter. Cetera Investment Advisers now owns 74,032 shares of the company’s stock worth $11,335,000 after purchasing an additional 43,265 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Up 0.1 %

Shares of NYSE CLX opened at $169.30 on Monday. The firm’s 50-day moving average price is $162.78 and its 200-day moving average price is $148.54. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The stock has a market capitalization of $20.96 billion, a price-to-earnings ratio of 58.99, a P/E/G ratio of 3.13 and a beta of 0.41. The Clorox Company has a 12-month low of $127.60 and a 12-month high of $171.35.

Clorox (NYSE:CLXGet Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.50. The firm had revenue of $1.76 billion for the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The business’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 EPS. On average, equities research analysts anticipate that The Clorox Company will post 6.85 EPS for the current fiscal year.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be given a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a dividend yield of 2.88%. The ex-dividend date of this dividend is Wednesday, January 29th. Clorox’s dividend payout ratio is 170.04%.

Insider Activity

In related news, EVP Angela C. Hilt sold 1,733 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at $2,229,719.92. This represents a 11.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.57% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on CLX shares. Evercore ISI cut their price objective on Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research report on Monday, October 14th. JPMorgan Chase & Co. boosted their price objective on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 11th. Barclays boosted their price objective on shares of Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a report on Friday, November 1st. TD Cowen upgraded shares of Clorox from a “sell” rating to a “hold” rating and boosted their target price for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, DA Davidson upped their price objective on Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $155.00.

Read Our Latest Stock Analysis on CLX

About Clorox

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Read More

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.